HomeCompareOCUP vs MRK

OCUP vs MRK: Dividend Comparison 2026

OCUP yields 170.94% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCUP wins by $49.51M in total portfolio value
10 years
OCUP
OCUP
● Live price
170.94%
Share price
$1.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.57M
Annual income
$23,046,519.63
Full OCUP calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — OCUP vs MRK

📍 OCUP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCUPMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCUP + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCUP pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCUP
Annual income on $10K today (after 15% tax)
$14,529.91/yr
After 10yr DRIP, annual income (after tax)
$19,589,541.69/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, OCUP beats the other by $19,581,213.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCUP + MRK for your $10,000?

OCUP: 50%MRK: 50%
100% MRK50/50100% OCUP
Portfolio after 10yr
$24.81M
Annual income
$11,528,158.88/yr
Blended yield
46.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

OCUP
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-6.1
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCUP buys
0
MRK buys
0
No recent congressional trades found for OCUP or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCUPMRK
Forward yield170.94%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$49.57M$56.8K
Annual income after 10y$23,046,519.63$9,798.13
Total dividends collected$46.28M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: OCUP vs MRK ($10,000, DRIP)

YearOCUP PortfolioOCUP Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$27,794$17,094.02$11,206$366.19+$16.6KOCUP
2$74,143$44,402.93$12,650$502.35+$61.5KOCUP
3$190,032$110,699.08$14,407$694.19+$175.6KOCUP
4$468,500$265,166.46$16,585$967.82+$451.9KOCUP
5$1,112,264$610,968.56$19,342$1,363.89+$1.09MOCUP
6$2,545,727$1,355,604.69$22,913$1,947.19+$2.52MOCUP
7$5,623,629$2,899,701.52$27,662$2,823.89+$5.60MOCUP
8$12,003,803$5,986,519.26$34,159$4,173.35+$11.97MOCUP
9$24,786,500$11,942,431.58$43,337$6,308.80+$24.74MOCUP
10$49,568,075$23,046,519.63$56,776$9,798.13+$49.51MOCUP

OCUP vs MRK: Complete Analysis 2026

OCUPStock

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Full OCUP Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this OCUP vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCUP vs SCHDOCUP vs JEPIOCUP vs OOCUP vs KOOCUP vs MAINOCUP vs JNJOCUP vs ABBVOCUP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.